OSCR
Oscar Health, Inc.
OSCR has the edge over SOPH overall, supported by stronger fundamentals and stronger modeled upside.
SOPH
SOPHiA GENETICS S.A.
SOPH has lower modeled downside risk, despite its lower overall score.
OSCR Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Healthy | |
| Strong | |
| Strong |
OSCR's revenue, profitability, cash flow and balance sheet are all currently healthy.
SOPH Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Under pressure | |
| Weak | |
| Unavailable |
SOPH's revenue is currently healthy, but its profitability and cash flow are under pressure. There isn't enough data to rate its balance sheet.
OSCR PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Forward | 12x | $31.94 | — |
| Current | 13x | $31.94 | — |
| Cheap | 21x | $52.73 | +65% |
| Fair | 35x | $87.23 | +173% |
| Expensive | 130x | $322 | +907% |
Historical ranges are pointers, not guarantees.
OSCR's PE is 13x, but its earnings don't support one, so it isn't a reliable read right now.
SOPH PE Valuation
SOPH has no meaningful PE right now: it lost money over the past year.
OSCR Forward outlook
| Metric | Outlook |
|---|---|
| Improving | |
| Strong growth | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Moderate |
Analysts expect strong earnings and revenue growth for OSCR, with profitability improving.
SOPH Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses shrinking | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| High |
Analysts expect SOPH's losses to shrink, with revenue growing.
OSCR Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $2.61 | +5.6% |
| Q3 2026 | $2.47 | +$3.47 |
| Q2 2026 | $1.45 | +$2.14 |
| Q1 2026 | -$0.54 | -235% |
| Q4 2025 | -$1.69 | -1790% |
| Q3 2025 | -$1.00 | -$0.92 |
| Q2 2025 | -$0.69 | -$0.54 |
| Q1 2025 | $0.40 | +$0.82 |
| Q4 2024 | $0.10 | +$1.32 |
OSCR has the edge over SOPH on earnings quality, reporting a profit while its opponent remains loss making.
SOPH Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q2 2026 | -$1.15 | -$0.05 |
| Q1 2026 | -$1.18 | -$0.18 |
| Q4 2025 | -$1.17 | -$0.22 |
| Q3 2025 | -$1.12 | -$0.03 |
| Q2 2025 | -$1.10 | -$0.08 |
| Q1 2025 | -$1.00 | +$0.12 |
| Q4 2024 | -$0.95 | +$0.27 |
| Q3 2024 | -$1.09 | -$0.02 |
SOPH is still losing money, but less than at its worst: $1.15 per share over the past year, against $1.51 at its worst in late 2022.
OSCR Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $5.1B | +72% |
| Q2 2026 | $4.9B | +70% |
| Q1 2026 | $4.6B | +53% |
| Q4 2025 | $2.8B | +17% |
| Q3 2025 | $3B | +23% |
| Q2 2025 | $2.9B | +29% |
| Q1 2025 | $3B | +42% |
| Q4 2024 | $2.4B | +67% |
OSCR has the edge over SOPH on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 3.5% | +7.8 points |
| Q2 2026 | 8% | +16 points |
| Q1 2026 | 15% | +5.4 points |
| Q4 2025 | -12% | -5.7 points |
| Q3 2025 | -4.3% | -2.3 points |
| Q2 2025 | -8.1% | -11 points |
| Q1 2025 | 9.8% | +1.1 points |
| Q4 2024 | -6.2% | +4 points |
OSCR has the edge over SOPH on profitability, with a higher operating margin.
SOPH Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q2 2026 | $23.3M | +27% |
| Q1 2026 | $21.7M | +22% |
| Q4 2025 | $21.7M | +22% |
| Q3 2025 | $19.5M | +23% |
| Q2 2025 | $18.3M | +16% |
| Q1 2025 | $17.8M | +13% |
| Q4 2024 | $17.7M | +4% |
| Q3 2024 | $15.9M | -2.8% |
SOPH's revenue has grown year over year for seven quarters in a row: $23M last quarter, up 27% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q2 2026 | -86% | +15 points |
| Q1 2026 | -80% | +11 points |
| Q4 2025 | -83% | +15 points |
| Q3 2025 | -92% | +5.1 points |
| Q2 2025 | -101% | -6.4 points |
| Q1 2025 | -90% | +29 points |
| Q4 2024 | -98% | +13 points |
| Q3 2024 | -97% | +4.6 points |
SOPH's operating margin was −86% last quarter, up 15 points from the same quarter a year ago.
OSCR Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$1.2B | -$238.2M |
| Q2 2026 | $2.1B | +316% |
| Q1 2026 | $2.6B | +200% |
| Q4 2025 | $662.8M | +95% |
| Q3 2025 | -$973.7M | -$466M |
| Q2 2025 | $499.8M | +2.1% |
| Q1 2025 | $869.5M | +38% |
| Q4 2024 | $340M | +17% |
OSCR has the edge over SOPH on cash generation, producing positive trailing cash flow while its opponent burns cash.
SOPH Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q2 2026 | -$10.4M | -$199K |
| Q1 2026 | -$17.1M | -$4.8M |
| Q4 2025 | -$9.3M | +$3.3M |
| Q3 2025 | -$8.9M | +$581K |
| Q2 2025 | -$10.2M | +$2.2M |
| Q1 2025 | -$12.2M | +$4.4M |
| Q4 2024 | -$12.5M | +$1M |
| Q3 2024 | -$9.5M | +$4.8M |
SOPH has burned cash in almost every quarter: −$46M over the past year, against −$44M the year before.
OSCR Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +3.9% | +13M shares |
| 1 year | +34% | +87.2M shares |
| 3 years | +55% | +123M shares |
| 5 years | +66% | +138M shares |
| Available history | +71% | +143M shares |
OSCR has 346M diluted shares, up 34% from a year ago.
| Quarter | Spent |
|---|---|
| Q4 2020 | — |
| Q3 2020 | — |
| Q2 2020 | — |
| Q1 2020 | — |
SOPH Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +3.8% | +2.7M shares |
| 1 year | +9.7% | +6.5M shares |
| 3 years | +14% | +9.3M shares |
| 5 years | +17% | +10.5M shares |
| Available history | +92% | +35.5M shares |
SOPH has the edge over OSCR on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q2 2026 | — |
| Q1 2026 | — |
| Q4 2025 | — |
| Q3 2025 | — |
| Q2 2025 | — |
| Q1 2025 | — |
| Q4 2024 | — |
| Q3 2024 | — |
SOPH hasn't bought back shares in the past year.
OSCR Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | -4.2x | Net Cash |
| Q2 2026 | -5.5x | Net Cash |
| Q1 2026 | -110.0x | Net Cash |
| Q1 2025 | -9.7x | Net Cash |
| Q4 2024 | -13.7x | Net Cash |
| Q3 2024 | -10.1x | Net Cash |
| Q2 2024 | -24.0x | Net Cash |
| Q1 2024 | -217.7x | Net Cash |
OSCR has more cash than debt.
SOPH Net Leverage
SOPH's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
OSCR Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 58.7 | Neutral |
| Stochastic | 44.9 | Neutral |
OSCR's weekly RSI is 59 (neutral) and its Stochastic is 45 (neutral).
SOPH Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 58.8 | Neutral |
| Stochastic | 56.5 | Neutral |
SOPH's weekly RSI is 59 (neutral) and its Stochastic is 57 (neutral).
OSCR PE vs Healthcare Sector
| Metric | OSCR | Sector median | Relative |
|---|---|---|---|
| PE | 13x | 26x | 50% below |
| PE % | 3 | 35 | 32 pts below |
OSCR is trading at 13x earnings, a 50% discount to the Healthcare sector's median of 26x, though its earnings don't support one.
SOPH PE vs Healthcare Sector
SOPH has no meaningful PE right now: it lost money over the past year.
OSCR Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $31.2 | 2.3% above |
| 20 week MA | $31.1 | 2.8% above |
| 50 week MA | $22.9 | 39% above |
| 100 week MA | $19.3 | 65% above |
| 200 week MA | $15.5 | 106% above |
OSCR is in an uptrend: it's above all five of its weekly moving averages, and 106% above its 200-week average.
SOPH Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $7.57 | 3.8% above |
| 20 week MA | $7.25 | 8.4% above |
| 50 week MA | $5.87 | 34% above |
| 100 week MA | $4.68 | 68% above |
| 200 week MA | $4.35 | 81% above |
SOPH is in an uptrend: it's above all five of its weekly moving averages, and 81% above its 200-week average.
OSCR Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2021 | $31.0 | $8.02 | -74% |
| 2022 | $8.02 | $2.21 | -72% |
| 2023 | $2.21 | $9.15 | +314% |
| 2024 | $9.15 | $13.8 | +51% |
| 2025 | $13.8 | $14.9 | +8% |
| 2026 YTD | $14.9 | $31.9 | +114% |
OSCR has the edge over SOPH on returns for 2026, with the stronger performance.
SOPH Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2021 | $16.8 | $13.7 | -19% |
| 2022 | $13.7 | $2.85 | -79% |
| 2023 | $2.85 | $4.71 | +65% |
| 2024 | $4.71 | $3.36 | -29% |
| 2025 | $3.36 | $4.73 | +41% |
| 2026 YTD | $4.73 | $7.86 | +66% |
SOPH is up 66% so far in 2026, after finishing lower in three of the previous five years.